CryoPort (NASDAQ:CYRX) CFO Sells $2,756,577.29 in Stock

CryoPort, Inc. (NASDAQ:CYRX) CFO Robert Stefanovich sold 169,427 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $16.27, for a total value of $2,756,577.29. Following the completion of the sale, the chief financial officer owned 109,850 shares of the company’s stock, valued at $1,787,259.50. The trade was a 60.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Robert Stefanovich also recently made the following trade(s):

• On Monday, March 23rd, Robert Stefanovich sold 1,094 shares of CryoPort stock. The shares were sold at an average price of $8.18, for a total value of $8,948.92.
• On Monday, March 16th, Robert Stefanovich sold 2,743 shares of CryoPort stock. The shares were sold at an average price of $8.00, for a total value of $21,944.00.
• On Thursday, March 12th, Robert Stefanovich sold 38,700 shares of CryoPort stock. The shares were sold at an average price of $7.76, for a total value of $300,312.00.

CryoPort Stock Performance

Shares of NASDAQ CYRX opened at $14.77 on Thursday. The firm has a market capitalization of $744.44 million, a price-to-earnings ratio of 10.94 and a beta of 1.90. The stock has a 50 day moving average price of $12.18 and a 200 day moving average price of $10.26. CryoPort, Inc. has a 52-week low of $6.16 and a 52-week high of $16.73.

CryoPort (NASDAQ:CYRX) last announced its quarterly earnings results on Monday, May 4th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). The firm had revenue of $47.80 million during the quarter, compared to analysts’ expectations of $44.86 million. CryoPort had a net margin of 41.57% and a negative return on equity of 7.92%. Analysts forecast that CryoPort, Inc. will post -0.85 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on CYRX. BTIG Research boosted their price target on CryoPort from $15.00 to $17.00 and gave the company a “buy” rating in a report on Tuesday, May 5th. Craig Hallum upped their target price on CryoPort from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, June 3rd. Jefferies Financial Group set a $13.50 target price on CryoPort in a report on Monday. Needham & Company LLC upped their target price on CryoPort from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Finally, Wall Street Zen upgraded CryoPort from a “sell” rating to a “hold” rating in a report on Monday, May 11th. Eight research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, CryoPort has a consensus rating of “Moderate Buy” and an average price target of $15.11.

Institutional Trading of CryoPort

A number of hedge funds have recently bought and sold shares of CYRX. Mak Capital One LLC acquired a new position in shares of CryoPort during the third quarter worth $7,756,000. UBS Group AG increased its position in shares of CryoPort by 112.7% during the third quarter. UBS Group AG now owns 1,331,521 shares of the company’s stock worth $12,623,000 after purchasing an additional 705,649 shares in the last quarter. Millennium Management LLC increased its position in shares of CryoPort by 23.8% during the fourth quarter. Millennium Management LLC now owns 3,244,802 shares of the company’s stock worth $31,150,000 after purchasing an additional 623,896 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its position in shares of CryoPort by 283.1% during the third quarter. Jacobs Levy Equity Management Inc. now owns 524,288 shares of the company’s stock worth $4,970,000 after purchasing an additional 387,440 shares in the last quarter. Finally, First Eagle Investment Management LLC acquired a new position in shares of CryoPort during the fourth quarter worth $2,996,000. Hedge funds and other institutional investors own 92.90% of the company’s stock.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.